MX2022007193A - Métodos para tratar la enfermedad de parkinson. - Google Patents

Métodos para tratar la enfermedad de parkinson.

Info

Publication number
MX2022007193A
MX2022007193A MX2022007193A MX2022007193A MX2022007193A MX 2022007193 A MX2022007193 A MX 2022007193A MX 2022007193 A MX2022007193 A MX 2022007193A MX 2022007193 A MX2022007193 A MX 2022007193A MX 2022007193 A MX2022007193 A MX 2022007193A
Authority
MX
Mexico
Prior art keywords
subject
treating
disease
methods
gad
Prior art date
Application number
MX2022007193A
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Alexandria Forbes
Original Assignee
Meiragtx Uk Ii Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiragtx Uk Ii Ltd filed Critical Meiragtx Uk Ii Ltd
Publication of MX2022007193A publication Critical patent/MX2022007193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022007193A 2019-12-12 2020-12-14 Métodos para tratar la enfermedad de parkinson. MX2022007193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947418P 2019-12-12 2019-12-12
PCT/US2020/064928 WO2021119615A1 (en) 2019-12-12 2020-12-14 Methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
MX2022007193A true MX2022007193A (es) 2022-09-19

Family

ID=76330812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007193A MX2022007193A (es) 2019-12-12 2020-12-14 Métodos para tratar la enfermedad de parkinson.

Country Status (10)

Country Link
US (1) US20230050187A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072568A4 (cg-RX-API-DMAC7.html)
JP (2) JP7758671B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220114028A (cg-RX-API-DMAC7.html)
AU (1) AU2020403266A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011584A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161322A1 (cg-RX-API-DMAC7.html)
IL (1) IL293776B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007193A (cg-RX-API-DMAC7.html)
WO (1) WO2021119615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026085129A1 (en) * 2024-10-15 2026-04-23 MeiraGTx Neuro I, LLC High-dose gad gene therapy for treating parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089583A2 (en) * 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
US20030087264A1 (en) * 2001-05-22 2003-05-08 Kaplitt Michael G. Transcriptional regulation of target genes
EP1893754A4 (en) * 2005-05-31 2009-01-21 Neurologix Inc NEW GLUTAMIC ACID DECARBOXYLASE (GAD) CHIMESES AND USE PROCESSES
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون

Also Published As

Publication number Publication date
KR20220114028A (ko) 2022-08-17
US20230050187A1 (en) 2023-02-16
EP4072568A1 (en) 2022-10-19
EP4072568A4 (en) 2024-02-07
JP7758671B2 (ja) 2025-10-22
BR112022011584A2 (pt) 2022-12-13
JP2023506007A (ja) 2023-02-14
IL293776B1 (en) 2026-07-01
WO2021119615A1 (en) 2021-06-17
AU2020403266A1 (en) 2022-08-04
CA3161322A1 (en) 2021-06-17
JP2025188191A (ja) 2025-12-25
IL293776A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
WO2007130474A3 (en) Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
ZA200900270B (en) Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
ATE280590T1 (de) Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen
WO2006050211A3 (en) Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2015524849A5 (cg-RX-API-DMAC7.html)
WO2009033027A3 (en) Suppression of scn9a gene expression and/or function for the treatment of pain
WO2004041258A3 (fr) Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
NZ601868A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2003093299A3 (en) Insulin-associated peptides with effects on cerebral health
BR9908084A (pt) Composto, processo para tratar um paciente afligido por algum distúrbio do sistema nervoso central e periférico, composição farmacêutica, e, uso de um composto
EP4230197A3 (en) High concentration medicant solutions for treating neurological disorders
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
WO2005037211A3 (en) Methods and compositions for the treatment of neurological disease
JP2022511568A5 (cg-RX-API-DMAC7.html)
MX2021004504A (es) Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos.
WO2021150969A8 (en) LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
MX2025002742A (es) R-trihexifenidilo para el tratamiento de trastornos del movimiento
Wal et al. Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments
BR112022011584A2 (pt) Métodos para tratamento da doença de parkinson
WO2006130639A3 (en) Novel glutamic acid decarboxylase (gad) chimera and methods of use
US9889117B2 (en) Method for treating and/or delaying the degeneration of Purkinje cells
WO2024182608A3 (en) Chemogenetics-based therapy for neurological disorders
BRPI0513337A (pt) composição e processo para melhor biodisponibilidade e melhor aplicação ao cérebro de ácido 5,5-difenil barbitúrico
RU2333918C2 (ru) ее3-СЕМЕЙСТВО БЕЛКОВ И СООТВЕТСТВУЮЩИЕ ДНК-ПОСЛЕДОВАТЕЛЬНОСТИ